Revvity (RVTY) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.27%. A quarter ago, it was expected that this maker of scientific instruments would post earnings of $1.13 per share when it actually produced earnings of $1.22, delivering a surprise of 7.96%.Over the last four quarter ...

Core Viewpoint - Revvity, Inc. has launched the EURORealTime APOE assay in European countries with CE mark approval, which is expected to enhance the company's position in the Alzheimer's disease treatment market by enabling accurate genotyping of the APOE gene [1][2]. Company Developments - The EURORealTime APOE PCR test allows for the simultaneous detection of the three most common APOE forms (E2, E3, E4) from a single blood sample, streamlining the genotyping process [3]. - The assay can be automated on Revvity's instruments, including the EUROIMMUN PreNAT II and chemagic 360 platforms, facilitating scalability in processing [3]. - Revvity's management is optimistic about the ongoing strong execution in its Diagnostics segment, which has shown slight revenue improvement in the second quarter of 2024 [7]. Industry Prospects - The global Alzheimer's therapeutics market was valued at $4.05 billion in 2022 and is projected to grow at a CAGR of approximately 19.9% from 2023 to 2030, driven by the rising prevalence of Alzheimer's disease and demand for effective treatments [6]. - The launch of the APOE assay is expected to significantly boost Revvity's business within this growing market [6]. Competitive Landscape - Eli Lilly's Kisunla (donanemab-azbt) received approval in Japan and the FDA for treating early symptomatic Alzheimer's, indicating strong competition in the Alzheimer's treatment space [8][9]. - Biogen, in collaboration with Eisai, has also made significant advancements with the approval of Leqembi for Alzheimer's treatment in Great Britain and the UAE, further intensifying competition [10][11]. - Intra-Cellular Therapies is actively enrolling patients in Phase 2 studies for treatments related to Alzheimer's, showcasing ongoing innovation in the industry [12][13].

Core Viewpoint - Revvity, Inc. (RVTY) is positioned for growth due to its strong product portfolio and focus on artificial intelligence (AI), despite facing challenges from foreign exchange volatility and integration risks [1][8][9] Company Performance - RVTY's shares have increased by 13.4% year to date, outperforming the industry growth of 0.7% and the S&P 500's increase of 20.8% during the same period [2] - The company has a market capitalization of $15.29 billion and projects a growth rate of 7.6% over the next five years [3] - RVTY's earnings have exceeded the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 5.02% [3] Product Development - The company has introduced several AI-driven solutions, including the PKeye Workflow Monitor and Signals Research Suite, enhancing its product offerings [3][4] - RVTY's software and informatics segment, particularly the Signals Software, has shown rapid growth, with three new SaaS-based solutions launched in the recent quarter [5] - The launch of a next-generation sequencing solution for Newborn Screening is expected to strengthen RVTY's market leadership [6] Financial Outlook - RVTY's diagnostic businesses have remained robust, with the immunodiagnostics franchise growing in the low double-digits [7] - The Zacks Consensus Estimate for third-quarter 2024 revenues is $678.2 million, reflecting a 1.1% increase from the previous year, while the EPS estimate is $1.13, indicating a year-over-year decline of 4.2% [10]

Core Viewpoint - Revvity, Inc. (RVTY) is positioned for growth due to its strong product portfolio and focus on artificial intelligence (AI), despite facing challenges from foreign exchange volatility and integration risks [1] Company Performance - Revvity's shares have increased by 9.1% year to date, outperforming the industry growth of 0.6% and the S&P 500's increase of 15% during the same period [2] - The company has a market capitalization of $14.51 billion and projects an 8.9% growth over the next five years, with earnings surpassing the Zacks Consensus Estimate in three of the last four quarters, averaging a surprise of 5.02% [3] Product and Innovation - The company is optimistic about its AI initiatives, including the introduction of PKeye Workflow Monitor and Signals Research Suite, which enhance laboratory management and data aggregation [5][6] - Revvity's software and informatics division, particularly the Signals Software, has shown strong growth, supported by the launch of three new SaaS-based offerings [6] - The launch of a next-generation sequencing solution for Newborn Screening is expected to help maintain market leadership, while the expansion of GMP reagent capacity is anticipated to generate additional revenue [7] Financial Outlook - Revvity's diagnostic businesses have remained robust, with the immunodiagnostics franchise growing in the low double-digits, and an expected rise in pharma and biotech spending may boost sales in the latter half of 2024 [8] - The Zacks Consensus Estimate for earnings per share (EPS) for 2024 has increased by 2.2% to $4.75, with second-quarter 2024 revenue estimates at $678.2 million, reflecting a 1.1% improvement year-over-year [11]

Core Insights - The article compares two medical services stocks, Pediatrix Medical Group (MD) and Revvity (RVTY), to determine which offers better value for investors [1] Valuation Metrics - Pediatrix Medical Group has a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Revvity has a Zacks Rank of 3 (Hold) [3] - MD has a forward P/E ratio of 8.04, significantly lower than RVTY's forward P/E of 25.15, suggesting MD is undervalued [5] - The PEG ratio for MD is 1.81, compared to RVTY's 2.83, indicating MD's expected earnings growth is more favorable [5] - MD's P/B ratio is 1.17, while RVTY's P/B ratio is 1.87, further supporting MD's valuation as more attractive [6] - Based on these metrics, MD receives a Value grade of A, while RVTY is rated C, highlighting MD's superior value proposition [6] Earnings Outlook - MD is noted for its improving earnings outlook, which enhances its attractiveness in the Zacks Rank model [7]

Revenue Details - Revvity operates under two segments: Life Sciences and Diagnostics [1] Financial Performance - Adjusted operating income for Revvity was $112.4 million, reflecting a 12% decrease from the prior-year quarter [2] - Revenues for Revvity totaled $691.7 million, down 2% year over year and 1% organically, missing the Zacks Consensus Estimate by 0.4% [16] - Revenues from the Life Sciences segment were $378 million, up 1.4% year over year, with an organic increase of 3% [8] - Revenues from the Diagnostics segment were $313.8 million, indicating a 6.7% decrease from the year-ago quarter, with a 6% organic decline [23] - Adjusted operating income for the Diagnostics segment was $97.9 million, up 14.9% from the year-ago quarter [24] - Selling, general and administrative expenses totaled $251.7 million, down 5.8% year over year, while research and development expenses were $48.1 million, down 15.9% [17] Cash Position - At the end of Q2 2024, Revvity had cash and cash equivalents of $1.95 billion, an increase from $1.70 billion at the end of the prior quarter [4] - Net cash provided by operating activities was $158.6 million, compared to a net cash used of $135.3 million in the year-ago quarter [18] 2024 Guidance - For 2024, Revvity expects adjusted EPS in the range of $4.70-$4.80 and revenues between $2.77-$2.79 billion, with the Zacks Consensus Estimate for EPS at $4.64 and revenues at $2.80 billion [12] Market Performance - Revvity's shares have gained 3.6% over the past six months, compared to the industry's growth of 6.7% and the S&P 500 Index's increase of 10.9% [19] - Revvity currently holds a Zacks Rank of 4 (Sell) [13]

Core Insights - Revvity reported second-quarter profit and sales that exceeded estimates due to higher demand for its diagnostic products [1][2] - The company raised its full-year adjusted EPS guidance, indicating positive future expectations [4] Financial Performance - Adjusted operating earnings per share (EPS) for the second quarter were $1.22, surpassing the average analyst estimate by $0.10 [2] - Revenue for the second quarter was $691.7 million, a decline of 2.5% year-over-year, but still above forecasts [2] - Revenue in the Diagnostics segment increased by 1.4% to $378.0 million, while the Life Sciences segment saw a decline of 6.7% to $313.8 million [3] Future Outlook - The adjusted EPS outlook for 2024 was raised to a range of $4.70 to $4.80 from the previous guidance of $4.55 to $4.75 [4] - Revenue outlook was narrowed to between $2.77 billion and $2.79 billion, compared to the earlier range of $2.76 billion to $2.82 billion [4] Market Reaction - Revvity shares rose by 3.5% to $119.18, reaching their highest level in almost a year [5]

Revvity, Inc. (NYSE:RVTY) Q2 2024 Earnings Conference Call July 29, 2024 8:00 AM ET Company Participants Steve Willoughby - SVP, IR Prahlad Singh - President & CEO Max Krakowiak - SVP & CFO Conference Call Participants Patrick Donnelly - Citi Jack Meehan - Nephron Research Puneet Souda - Leerink Partners Vijay Kumar - Evercore Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Catherine Schulte - Baird Luke Sergott - Barclays Michael Ryskin - Bank of America Paul Knight - KeyBanc Rachel Vatnsdal - JP Morgan ...

Revvity (RVTY) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $1.21 per share a year ago. These figures are adjusted for nonrecurring items. Over the last four quarters, the company has surpassed consensus EPS estimates three times. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the ear ...

FOR IMMEDIATE RELEASE July 29, 2024 • Revenue of $692 million; (2)% reported growth; (1)% organic growth • GAAP EPS of $0.45; Adjusted EPS from continuing operations of $1.22 • Raises full year 2024 adjusted EPS guidance Adjusted earnings per share from continuing operations for the quarter was $1.22, as compared to $1.21 in the same period a year ago. Adjusted revenue for the quarter was $692 million, as compared to $709 million in the same period a year ago. Adjusted operating income was $199 million, as ...